A Look at DARZALEX® (daratumumab) Treatment Regimen in Newly Diagnosed Multiple Myeloma Patients Who are Transplant Eligible
DARZALEX® is a CD38-directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma.
Multiple Myeloma
MULTIPLE MYELOMA ADVISOR
FEATURED CONTENT
-
Reliability of Laboratory-Developed Tests Called Into Question
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire. -
Similar Outcomes in VRd and KRd in Multiple Myeloma
VRd is a frequently used regimen in patients with newly diagnosed MM. -
Diagnosis, Risk-Stratification, Management Updates in Myelodysplastic Syndromes
An overview of the diagnosis and management of MDS, including recent treatment, was discussed in a paper published in the American Journal of Hematology. -
How the Coronavirus Pandemic May Affect Cancer Clinical Trials
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
VIDEO SERIES
MULTIPLE MYELOMA NEWS
Depression Common Among Patients With a Myeloproliferative Neoplasm
Anticipatory Management, Adherence Strategies Optimize MM Treatment With Selinexor
Comparison of Triplet vs Doublet Regimen for the Treatment of Plasma Cell Myeloma in Older Patients
VTE Risk Remains High in Newly Diagnosed Multiple Myeloma Despite Thromboprophylaxis
Daratumumab for Multiple Myeloma With High-Risk Cytogenetic Factors
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma
